Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.63 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768682 | 1.00 | GBA1 (0.63) | GBA1SLC1A3SLC1A2SLC1A1LARS1 | |
| Hydrochloric Acid SCHEMBL7662277 | 0.98 | GBA1 (0.61) | GBA1SLC1A3SLC1A2SLC1A1LARS1 | |
| Hydrochloric Acid SCHEMBL382132 | 0.98 | GBA1 (0.61) | GBA1SLC1A3SLC1A2SLC1A1LARS1 | |
| SCHEMBL1768631 | 0.87 | SLC1A3 (0.55) | GBA1SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL27888805 | 0.87 | SLC1A3 (0.55) | GBA1SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6739604 | 0.84 | GBA1 (0.65) | GBA1SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6739598 | 0.84 | GBA1 (0.65) | GBA1SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL13585322 | 0.83 | ALDH1A1 (0.54) | GBA1SLC1A3SLC1A2SLC1A1LARS1 | |
| SCHEMBL2235887 | 0.83 | ALDH1A1 (0.54) | GBA1SLC1A3SLC1A2SLC1A1LARS1 | |
| SCHEMBL1768570 | 0.82 | CYP19A1 (0.54) | GBA1MMP1CA2MMP2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102844327-B | Template-fixed peptidomimetics with CXCR7 modulatory activity | 波利弗尔股份公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-102712676-B | There is the peptidomimetic that the template of CCR10 antagonistic activity is fixing | 波利弗尔股份公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-102844327-A | Template-fixed peptidomimetics with CXCR7 modulatory activity | POLYPHOR AG | 2012-12-26 | — | — | CN | disclosed |
| CN-102712676-A | Template-fixed peptidomimetics with CCR10 antagonistic activty | POLYPHOR AG | 2012-10-03 | — | — | CN | disclosed |
| EP-1074543-B1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA PHARMA CO LTD (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1250935-A1 | REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-0896003-A1 | Peptides for reducing or inhibiting bone resorption, angiogenesis and restenosis | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1999-02-10 | — | — | EP | disclosed |
| EP-0873357-A2 | ANTITHROMBOTIC AGENTS AND METHODS OF USE | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998016256-A1 | MAGNETIC RESONANCE IMAGING OF THROMBI | THE BURNHAM INSTITUTE (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1997025343-A2 | ANTITHROMBOTIC AGENTS AND METHODS OF USE | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | ITGB3, ITGAV, ITGB1 | GBA1 2767/4885SLC1A3 1301/4885SLC1A2 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.